Trial Profile
A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary)
- Indications Adenoid cystic carcinoma; Advanced breast cancer; Burkitt's lymphoma; Cervical cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Head and neck cancer; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Solid tumours; Waldenstrom's macroglobulinaemia
- Focus Pharmacodynamics
- Sponsors Bayer
- 24 Mar 2018 Results exploring the relationship between copanlisib pharmacokinetic (PK) and pharmacodynamic (PD) effects in a phase I study in subjects with NHL and solid tumors presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 12 Dec 2017 Results assessing dose dependent pharmacodynamic effects of copanlisib relative to plasma exposure presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 07 Dec 2017 According to a Bayer media release, data from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH).